MNG943
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.672
- INTERFERON_GAMMA_RESPONSE+0.633
- IL6_JAK_STAT3_SIGNALING+0.622
- INFLAMMATORY_RESPONSE+0.621
- TNFA_SIGNALING_VIA_NFKB+0.585
- INTERFERON_ALPHA_RESPONSE+0.543
- COMPLEMENT+0.487
- KRAS_SIGNALING_UP+0.453
- IL2_STAT5_SIGNALING+0.375
- APOPTOSIS+0.283
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.543
- PROTEIN_SECRETION-0.406
- MYC_TARGETS_V1-0.384
- UNFOLDED_PROTEIN_RESPONSE-0.355
- UV_RESPONSE_DN-0.344
- ADIPOGENESIS-0.332
- DNA_REPAIR-0.315
- MYC_TARGETS_V2-0.299
- FATTY_ACID_METABOLISM-0.287
- GLYCOLYSIS-0.272
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG728 | — | — | 0.897 |
| 2 | MNG303 | — | — | 0.884 |
| 3 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.879 |
| 4 | MDT-AP-2234 | Med | Medulloblastoma | 0.873 |
| 5 | R243 | — | — | 0.872 |
| 6 | SRR1369219 | GTEX | — | 0.871 |
| 7 | SRR1079168 | GTEX | — | 0.865 |
| 8 | SRR10842366 | — | — | 0.860 |
| 9 | R252 | — | — | 0.859 |
| 10 | SRR1370173 | GTEX | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.672 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.633 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.622 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.621 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.585 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.543 | Inavolisib | — uncovered |
| COMPLEMENT | 0.487 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.453 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.375 | Idelalisib | — uncovered |
| APOPTOSIS | 0.283 | Idelalisib | — uncovered |
| COAGULATION | 0.276 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.272 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.249 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.136 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.132 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.123 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.111 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.107 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.089 | Inavolisib | — uncovered |
| HYPOXIA | 0.079 | Idelalisib | — uncovered |